Deloitte acquires Iperion Life Sciences Consultancy
pharmafile | May 7, 2021 | News story | Medical Communications | marketing, sales
Deloitte have announced the acquisition of Iperion Life Sciences Consultancy, a globally-operating firm working to support life sciences companies and regulatory bodies in their digital transformation.
Iperion will now be known as ‘Iperion – a Deloitte business’ and will run as part of Deloitte’s Risk Advisory function, looking at human medicine safety, outcomes, and experiences through standardised, regulated product information.
Iperion’s co-founder, Frits Stulp, will serve as a partner within the Deloitte Risk operation, and his counterpart Karel Bastiaanssen has committed to supporting the integration and growth of Iperion in the coming years.
Harvey Christophers, Managing Partner at Deloitte Risk Advisory, said: “Standardised product information is a domain Deloitte has been investing in globally as part of its Life Sciences Regulatory practice, particularly in Europe recently – and in the Netherlands specifically – following the move of EMA.
“Iperion is an expert in the market and we are eager to see what we can deliver together. The knowledge and passion of Iperion’s young team attracted us, in particular. We are joining forces to help our clients do business responsibly, build trust and have a real impact.”
In a statement from Iperion, it stated that both parties hope to make a greater contribution to the accelerated approval of new or improved medicines, as well as the provision of high-quality information to patients and the healthcare sector.
Frits Stulp said: “Deloitte and Iperion have been collaborating on innovative digitisation projects at pharmaceutical companies for years. The integration with Deloitte is a logical next step to further shape the ambitions and growth strategy of both organisations in this area by, among other things, joining our efforts to implement the data standard ISO IDMP”.
Iperion co-founder, Karel Bastiaanssen, added: “In the drive to make a difference in this industry we have identified common core values in Deloitte. This merger is a deliberate step in our mission towards standardised and structured data, leading to improved speed of innovation and information transparency.
“The goal, ultimately, is better medicines and better information provisioning in the life sciences ecosystem.”
Kat Jenkins
Related Content
Exscientia buys Austrian cancer cell screening company for €50 million
UK-based AI pioneers Exscientia has announced the purchase of rival AI firm Allcyte for €50 …
Novartis CEO sets aside $700 million to settle bribery lawsuit
Vas Narasimhan, Novartis’ CEO, has set aside $700 million to settle a bribery lawsuit in …
EU pharmaceutical industry lost €16.5 billion in sales as staff shift to patent infringing firms
A report from the European Union Intellectual Property Office (EUIPO) has said ‘counterfeit’ drugs cost …
